Loading stock data…
QURE
$19.13-0.82 (-4.11%)
Pre-Market$19.50+0.37 (+1.93%)· Last close May 1
uniQure N.V.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
uniQure N.V. in the Healthcare sector is trading at $19.13. The stock is currently near its 52-week low of $8.73, remaining 24.9% below its 200-day moving average. Technical signals show neutral RSI of 56 and bullish MACD crossover, explaining why QURE maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 56) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$19.13
Potential Upside
5%
Whystock Fair Value$20.09
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Buy
Mean target$38.94+103.6%
Range$9.03 – $96.07
Fundamentals
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding....
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.11B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.75
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-100.04%
Volume
Today's trading volume
1.53M
Recent News
Sector Update: Health Care Stocks Gain Late Afternoon
Health care stocks rose late Thursday afternoon with the NYSE Health Care Index climbing 2.6% and th
uniQure N.V. (QURE) Stock Posts 30% Growth from Last Year
uniQure N.V. (NASDAQ:QURE) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock registered a 32.28 percent growth in the past year and a 24.84 percent year-to-date decline. On March 11, Mizuho Securities upgraded its price target on uniQure to $35 from $12. Similarly, RBC Capital also upgraded its price […]
Is Regulatory Scrutiny of AMT-130 Quietly Rewriting uniQure’s (QURE) Gene Therapy Investment Story?
In recent weeks, uniQure has faced intensified scrutiny as multiple law firms advanced securities class actions alleging misleading disclosures around FDA interactions and the pivotal study design for its Huntington’s disease gene therapy candidate, AMT-130. At the same time, sharp public criticism from FDA officials over AMT-130’s clinical data and study design has put a spotlight on uniQure’s regulatory communication practices, raising fresh questions about how the company manages one of...
Barclays Reaffirms Equal Weight Rating for uniQure (QURE)
uniQure N.V. (NASDAQ:QURE) is one of the 7 best small-cap healthcare stocks to buy according to hedge funds. On March 23, Barclays analyst Eliana Merle reduced the price target on uniQure N.V. (NASDAQ:QURE) from $31 to $25. The analyst reaffirmed an Equal Weight rating on the shares, which still offer a potential upside of more […]
Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.